Location History:
- Stucksund, SE (2015)
- Stocksund, SE (2011 - 2016)
- Stockholm, SE (2021)
- Lidingö, SE (2023)
Company Filing History:
10 out of 13 
2 out of 2 
1 out of 1,289 
Years Active: 2011-2023
Title: Mathias Uhlén: Innovator in Medical Treatments
Introduction
Mathias Uhlén is a prominent inventor based in Stocksund, Sweden. He has made significant contributions to the field of medical treatments, particularly focusing on conditions related to fatty liver disease. With a total of 12 patents to his name, Uhlén's work is recognized for its innovative approaches to health and wellness.
Latest Patents
One of Uhlén's latest patents involves a composition for the treatment of fatty liver-related conditions. This composition includes a combination of serine, glycine, betaine, and other amino acids, along with N-acetyl cysteine and various nicotinamide compounds. The specific molar ratios of these components are carefully defined to optimize their effectiveness in treating medical conditions such as non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), type 2 diabetes, obesity, insulin resistance, and dyslipidemia.
Career Highlights
Throughout his career, Uhlén has worked with notable companies, including Atlas Antibodies AB and Scandibio Therapeutics AB. His expertise in biochemistry and medical research has positioned him as a leader in developing innovative solutions for complex health issues.
Collaborations
Uhlén has collaborated with esteemed colleagues in his field, including Fredrik Pontén and Karin Jirström. These partnerships have further enhanced his research and development efforts, leading to impactful advancements in medical treatments.
Conclusion
Mathias Uhlén's contributions to medical innovation, particularly in the treatment of fatty liver-related conditions, highlight his role as a significant inventor in the healthcare sector. His ongoing work continues to inspire advancements in medical science and improve patient outcomes.